SOLV vs. GEHC, PHG, ZBH, SNN, PEN, GKOS, STVN, BLCO, INSP, and NARI
Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry.
Solventum vs.
Solventum (NYSE:SOLV) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
GE HealthCare Technologies has higher revenue and earnings than Solventum.
GE HealthCare Technologies received 21 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 57.89% of users gave GE HealthCare Technologies an outperform vote while only 5.56% of users gave Solventum an outperform vote.
In the previous week, GE HealthCare Technologies had 7 more articles in the media than Solventum. MarketBeat recorded 14 mentions for GE HealthCare Technologies and 7 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.30 beat Solventum's score of 0.87 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.
GE HealthCare Technologies has a net margin of 8.56% compared to Solventum's net margin of 0.00%. GE HealthCare Technologies' return on equity of 25.19% beat Solventum's return on equity.
82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.3% of GE HealthCare Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Solventum presently has a consensus price target of $68.29, indicating a potential downside of 7.21%. GE HealthCare Technologies has a consensus price target of $96.00, indicating a potential upside of 13.29%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.
Summary
GE HealthCare Technologies beats Solventum on 14 of the 14 factors compared between the two stocks.
Get Solventum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solventum Competitors List
Related Companies and Tools
This page (NYSE:SOLV) was last updated on 1/20/2025 by MarketBeat.com Staff
